[托法替布治疗儿童风湿性疾病的最新研究]
[Recent research on tofacitinib in the treatment of pediatric rheumatic diseases].
作者信息
Zhou Shi-Hai, Xiong Ya-Qun, Chen Ya
机构信息
Department of Pharmacy, Guihang Guiyang Hospital, Guiyang 550001, China.
出版信息
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Apr 15;24(4):447-453. doi: 10.7499/j.issn.1008-8830.2201081.
Abstract
Tofacitinib is a Janus kinase inhibitor and can block the Janus kinase-signal transducer and activator of transcription signal transduction pathway and reduce the production and release of a variety of cytokines. It has great potential in the treatment of various rheumatic diseases with a rapid onset of action and can reduce corticosteroid dependence and related adverse events. The therapeutic effect of tofacitinib in adult patients has been confirmed, and it has been increasingly used in pediatric patients in recent years. This article reviews the clinical application of tofacitinib in the treatment of pediatric autoimmune diseases.
摘要
托法替布是一种Janus激酶抑制剂，可阻断Janus激酶-信号转导子和转录激活子信号转导通路，减少多种细胞因子的产生和释放。它在治疗各种风湿性疾病方面具有巨大潜力，起效迅速，可减少对皮质类固醇的依赖及相关不良事件。托法替布在成年患者中的治疗效果已得到证实，近年来在儿科患者中的应用也越来越多。本文综述了托法替布在儿科自身免疫性疾病治疗中的临床应用。
相似文献
1
[Recent research on tofacitinib in the treatment of pediatric rheumatic diseases].[托法替布治疗儿童风湿性疾病的最新研究]
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Apr 15;24(4):447-453. doi: 10.7499/j.issn.1008-8830.2201081.
2
The off-label uses profile of tofacitinib in systemic rheumatic diseases.托法替布在全身性风湿性疾病中的超说明书用药情况
Int Immunopharmacol. 2020 Jun;83:106480. doi: 10.1016/j.intimp.2020.106480. Epub 2020 Apr 10.
3
Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.类风湿关节炎和银屑病关节炎中的骨免疫学：托法替布对骨骼受累的潜在影响。
Clin Rheumatol. 2020 Mar;39(3):727-736. doi: 10.1007/s10067-020-04930-x. Epub 2020 Jan 22.
4
Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus.托法替尼治疗难治性天疱疮：天疱疮的一种可能替代治疗方法。
Dermatol Ther. 2018 Sep;31(5):e12696. doi: 10.1111/dth.12696. Epub 2018 Sep 11.
5
Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.托法替布，一种口服的 Janus 激酶抑制剂：皮肤病学中的应用前景
Curr Med Chem. 2017 May 31;24(11):1158-1167. doi: 10.2174/1874467210666170113104503.
6
An evaluation of tofacitinib for the treatment of psoriatic arthritis.评估托法替布治疗银屑病关节炎。
Expert Opin Pharmacother. 2019 Nov;20(16):1953-1960. doi: 10.1080/14656566.2019.1657404. Epub 2019 Aug 28.
7
The emerging safety profile of JAK inhibitors in rheumatic disease.新型 JAK 抑制剂在风湿性疾病中的安全性概况。
Nat Rev Rheumatol. 2017 Apr;13(4):234-243. doi: 10.1038/nrrheum.2017.23. Epub 2017 Mar 2.
8
Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.托法替尼抑制角质细胞中的 Janus 激酶-信号转导与转录激活因子信号通路。
Acta Derm Venereol. 2018 Aug 29;98(8):772-775. doi: 10.2340/00015555-2960.
9
[Anti-rheumatic effect of JAK-inhibitors].[JAK抑制剂的抗风湿作用]
Nihon Rinsho Meneki Gakkai Kaishi. 2012;35(2):112-7. doi: 10.2177/jsci.35.112.
10
[A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].风湿病慢性炎症的一种新治疗选择：Janus激酶抑制剂（JAK）
Rev Med Suisse. 2014 Jan 22;10(414):187-91.
引用本文的文献
1
Tofacitinib treatment of systemic juvenile idiopathic arthritis: a case report and literature review.托法替布治疗全身型幼年特发性关节炎：一例报告及文献综述
Front Pediatr. 2025 Feb 13;13:1482762. doi: 10.3389/fped.2025.1482762. eCollection 2025.
本文引用的文献
1
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.托法替尼治疗幼年特发性关节炎：一项双盲、安慰剂对照、撤药阶段 3 随机试验。
Lancet. 2021 Nov 27;398(10315):1984-1996. doi: 10.1016/S0140-6736(21)01255-1. Epub 2021 Nov 9.
2
Role of Janus Kinase Inhibitors in Therapy of Psoriasis.Janus激酶抑制剂在银屑病治疗中的作用。
J Clin Med. 2021 Sep 22;10(19):4307. doi: 10.3390/jcm10194307.
3
Juvenile Idiopathic Arthritis Treatment Updates.青少年特发性关节炎治疗进展
Rheum Dis Clin North Am. 2021 Nov;47(4):545-563. doi: 10.1016/j.rdc.2021.07.009. Epub 2021 Sep 2.
4
Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.靶向自身免疫性疾病和癌症中的 JAK-STAT 通路：聚焦于分子机制和治疗潜力。
Biochem Pharmacol. 2021 Nov;193:114760. doi: 10.1016/j.bcp.2021.114760. Epub 2021 Sep 4.
5
Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis.类风湿关节炎中信号通路及其抑制剂的最新进展。
Clin Immunol. 2021 Sep;230:108793. doi: 10.1016/j.clim.2021.108793. Epub 2021 Jul 6.
6
Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.幼年特发性皮肌炎中干扰素的最新研究进展：发病机制与治疗。
Curr Opin Rheumatol. 2021 Sep 1;33(5):371-377. doi: 10.1097/BOR.0000000000000816.
7
Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease.托法替尼治疗儿童和青年成人群体中儿童发病的药物难治性炎症性肠病。
J Pediatr Gastroenterol Nutr. 2021 Sep 1;73(3):e57-e62. doi: 10.1097/MPG.0000000000003190.
8
Evaluation of tofacitinib citrate bioequivalence based on pharmacokinetic parameters in healthy Chinese subjects.枸橼酸托法替布在中国健康受试者中的药代动力学参数的生物等效性评价。
Int J Clin Pharmacol Ther. 2021 Apr;59(4):343-352. doi: 10.5414/CP203751.
9
JAK/STAT and VEGF/PAK1 signaling as emerging targets for topical treatment of psoriasis: a pilot study.JAK/STAT和VEGF/PAK1信号通路作为银屑病局部治疗的新兴靶点：一项初步研究。
Int J Clin Exp Pathol. 2020 Dec 1;13(12):3111-3119. eCollection 2020.
10
Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.斑秃：诊断、免疫学发病机制及治疗选择的综述。
Clin Exp Med. 2021 May;21(2):215-230. doi: 10.1007/s10238-020-00673-w. Epub 2021 Jan 1.
Zotero 插件